Galmed Pharmaceuticals (GLMD) Cash from Investing Activities (2013 - 2025)

Galmed Pharmaceuticals' Cash from Investing Activities history runs 13 years deep, the most recent figure standing at $1.4 million for Q4 2025.

• In Q4 2025, Cash from Investing Activities rose 140.24% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at -$3.4 million (down 203.78% YoY), while the FY2025 annual figure was -$3.4 million, down 203.78% from the prior year.
• Cash from Investing Activities was $1.4 million for Q4 2025 at Galmed Pharmaceuticals, up from -$3000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $6.4 million in Q4 2021 to a low of -$4.6 million in Q2 2025.
• Historically, Cash from Investing Activities has averaged $1.3 million across 5 years, with a median of $1.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities surged 483.76% in 2022, then plunged 428.23% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $6.4 million in 2021, then tumbled by 69.01% to $2.0 million in 2022, then climbed by 15.16% to $2.3 million in 2023, then slumped by 255.73% to -$3.5 million in 2024, then jumped by 140.24% to $1.4 million in 2025.
• The last three Cash from Investing Activities figures came in at $1.4 million (Q4 2025), -$3000.0 (Q3 2025), and -$4.6 million (Q2 2025), per Business Quant data.